{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:04:11Z","timestamp":1768889051147,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"crossref","award":["2308085MH290"],"award-info":[{"award-number":["2308085MH290"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010814","name":"Anhui Provincial Department of Education","doi-asserted-by":"publisher","award":["DTR2024018"],"award-info":[{"award-number":["DTR2024018"]}],"id":[{"id":"10.13039\/501100010814","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Projects of Scientific Research Programs of Higher Education Institutions in Anhui Province","award":["2024AH050950"],"award-info":[{"award-number":["2024AH050950"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-025-03011-x","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T07:47:30Z","timestamp":1765352850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Mei-jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-nuo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-pei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4254-0796","authenticated-orcid":false,"given":"Yuan-jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"Suppl 1","key":"3011_CR1","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/apt.17930","volume":"59","author":"SK Bansal","year":"2024","unstructured":"Bansal SK, Bansal MB. Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity. Aliment Pharmacol Ther. 2024;59(Suppl 1):S10\u201322. https:\/\/doi.org\/10.1111\/apt.17930.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl","key":"3011_CR2","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32\u201350. https:\/\/doi.org\/10.3350\/cmh.2024.0431.","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"3011_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101185","volume":"6","author":"F Carli","year":"2024","unstructured":"Carli F, Della Pepa G, Sabatini S, Vidal Puig A, Gastaldelli A. Lipid metabolism in MASLD and MASH: from mechanism to the clinic. JHEP Rep. 2024;6(12):101185. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101185.","journal-title":"JHEP Rep"},{"key":"3011_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1433857","volume":"12","author":"R Sandireddy","year":"2024","unstructured":"Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh BK. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front Cell Dev Biol. 2024;12:1433857. https:\/\/doi.org\/10.3389\/fcell.2024.1433857.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"3011_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595.","journal-title":"Gut"},{"issue":"4","key":"3011_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/liv.15852","volume":"44","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Paik J, et al. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Liver Int. 2024;44(4):1061\u201370. https:\/\/doi.org\/10.1111\/liv.15852.","journal-title":"Liver Int"},{"issue":"7","key":"3011_CR7","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/liv.15930","volume":"44","author":"S Petta","year":"2024","unstructured":"Petta S, Targher G, Romeo S, et al. The first MASH drug therapy on the horizon: current perspectives of resmetirom. Liver Int. 2024;44(7):1526\u201336. https:\/\/doi.org\/10.1111\/liv.15930.","journal-title":"Liver Int"},{"key":"3011_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111675","volume":"211","author":"B Brouwers","year":"2024","unstructured":"Brouwers B, Rao G, Tang Y, Rodr\u00edguez \u00c1, Glass LC, Hartman ML. Incretin-based investigational therapies for the treatment of MASLD\/MASH. Diabetes Res Clin Pract. 2024;211:111675. https:\/\/doi.org\/10.1016\/j.diabres.2024.111675.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"3011_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s43587-025-00811-7","volume":"5","author":"Y Yang","year":"2025","unstructured":"Yang Y, Jn-Simon N, He Y, et al. A BCL-xL\/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice. Nat Aging. 2025;5(3):386\u2013400. https:\/\/doi.org\/10.1038\/s43587-025-00811-7.","journal-title":"Nat Aging"},{"issue":"10","key":"3011_CR10","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.cmet.2024.08.010","volume":"36","author":"X Wei","year":"2024","unstructured":"Wei X, Wu D, Li J, et al. Myeloid beta-arrestin 2 depletion attenuates metabolic dysfunction-associated steatohepatitis via the metabolic reprogramming of macrophages. Cell Metab. 2024;36(10):2281-2297.e7. https:\/\/doi.org\/10.1016\/j.cmet.2024.08.010.","journal-title":"Cell Metab"},{"issue":"1","key":"3011_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02108-x","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y, Yang P, Ye J, Xu Q, Wu J, Wang Y. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024;23(1):117. https:\/\/doi.org\/10.1186\/s12944-024-02108-x.","journal-title":"Lipids Health Dis"},{"issue":"6","key":"3011_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jhep.2024.12.006","volume":"82","author":"L Xiang","year":"2025","unstructured":"Xiang L, Wang G, Zhuang Y, et al. Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82(6):967\u201378. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.006.","journal-title":"J Hepatol"},{"issue":"21","key":"3011_CR13","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"issue":"5","key":"3011_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101363","volume":"7","author":"A Moolla","year":"2025","unstructured":"Moolla A, Poolman T, Othonos N, et al. Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD. JHEP Rep. 2025;7(5):101363. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101363.","journal-title":"JHEP Rep"},{"issue":"1","key":"3011_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","volume":"23","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Frias JP, Lucas KJ, et al. Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH\/MASH and type 2 diabetes in a randomized phase 2 study. Clin Gastroenterol Hepatol. 2025;23(1):103\u201313. https:\/\/doi.org\/10.1016\/j.cgh.2024.02.022.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"3011_CR16","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","volume":"22","author":"SS Shankar","year":"2024","unstructured":"Shankar SS, Daniels SJ, Robertson D, et al. Safety and efficacy of novel incretin co-agonist cotadutide in biopsy-proven noncirrhotic MASH with fibrosis. Clin Gastroenterol Hepatol. 2024;22(9):1847-1857.e11. https:\/\/doi.org\/10.1016\/j.cgh.2024.04.017.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"3011_CR17","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037\u201348. https:\/\/doi.org\/10.1038\/s41591-024-03018-2.","journal-title":"Nat Med"},{"issue":"4","key":"3011_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2401755.","journal-title":"N Engl J Med"},{"issue":"4","key":"3011_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"issue":"4","key":"3011_CR20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","volume":"79","author":"M Romero-G\u00f3mez","year":"2023","unstructured":"Romero-G\u00f3mez M, Lawitz E, Shankar RR, et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. 2023;79(4):888\u201397. https:\/\/doi.org\/10.1016\/j.jhep.2023.05.013.","journal-title":"J Hepatol"},{"issue":"1","key":"3011_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","volume":"74","author":"S Ha","year":"2024","unstructured":"Ha S, Wong VW, Zhang X, Yu J. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma. Gut. 2024;74(1):141\u201352. https:\/\/doi.org\/10.1136\/gutjnl-2024-332398.","journal-title":"Gut"},{"issue":"3","key":"3011_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.pcd.2024.03.005","volume":"18","author":"L Fang","year":"2024","unstructured":"Fang L, Li J, Zeng H, Liu J. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: a systematic review and meta-analysis. Prim Care Diabetes. 2024;18(3):268\u201376. https:\/\/doi.org\/10.1016\/j.pcd.2024.03.005.","journal-title":"Prim Care Diabetes"},{"issue":"8","key":"3011_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0289616","volume":"18","author":"C Liao","year":"2023","unstructured":"Liao C, Liang X, Zhang X, Li Y. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis. PLoS One. 2023;18(8):e0289616. https:\/\/doi.org\/10.1371\/journal.pone.0289616.","journal-title":"PLoS One"},{"issue":"3","key":"3011_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/17474124.2023.2172397","volume":"17","author":"Y Gu","year":"2023","unstructured":"Gu Y, Sun L, He Y, et al. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials. Expert Rev Gastroenterol Hepatol. 2023;17(3):273\u201382. https:\/\/doi.org\/10.1080\/17474124.2023.2172397.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"7","key":"3011_CR25","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/jgh.16559","volume":"39","author":"K Malandris","year":"2024","unstructured":"Malandris K, Papandreou S, Vasilakou D, et al. Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis. J Gastroenterol Hepatol. 2024;39(7):1219\u201329. https:\/\/doi.org\/10.1111\/jgh.16559.","journal-title":"J Gastroenterol Hepatol"},{"key":"3011_CR26","unstructured":"Registration of systematic reviews in PROSPERO. Available at: https:\/\/www.crd.york.ac.uk\/PROSPERO\/. Accessed 20 July, 2025."},{"key":"3011_CR27","unstructured":"Online tool to evaluate the certainty and importance of the evidence-GRADE pro. Available at: https:\/\/www.gradepro.org\/. Accessed 20 July, 2025."},{"key":"3011_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2024.102882","volume":"46","author":"ANMS Islam","year":"2024","unstructured":"Islam ANMS, Sultana H, Nazmul Hassan Refat M, Farhana Z, Abdulbasah Kamil A, Meshbahur Rahman M. The global burden of overweight-obesity and its association with economic status, benefiting from STEPs survey of WHO member states: a meta-analysis. Prev Med Rep. 2024;46:102882. https:\/\/doi.org\/10.1016\/j.pmedr.2024.102882.","journal-title":"Prev Med Rep"},{"issue":"12","key":"3011_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/nu15122782","volume":"15","author":"G Novelli","year":"2023","unstructured":"Novelli G, Cassadonte C, Sbraccia P, Biancolella M. Genetics: a starting point for the prevention and the treatment of obesity. Nutrients. 2023;15(12):2782. https:\/\/doi.org\/10.3390\/nu15122782.","journal-title":"Nutrients"},{"issue":"1","key":"3011_CR30","doi-asserted-by":"publisher","DOI":"10.3402\/gha.v9.29625","volume":"9","author":"M Aceves-Martins","year":"2016","unstructured":"Aceves-Martins M, Llaurad\u00f3 E, Tarro L, Sol\u00e0 R, Giralt M. Obesity-promoting factors in Mexican children and adolescents: challenges and opportunities. Glob Health Action. 2016;9(1):29625. https:\/\/doi.org\/10.3402\/gha.v9.29625.","journal-title":"Glob Health Action"},{"issue":"6","key":"3011_CR31","doi-asserted-by":"publisher","first-page":"763","DOI":"10.29271\/jcpsp.2022.06.763","volume":"32","author":"AR Bekhwani","year":"2022","unstructured":"Bekhwani AR, Khan M. Various risk factors of overweight and obesity among children aged 5-16 years. J Coll Physicians Surg Pak. 2022;32(6):763\u20137. https:\/\/doi.org\/10.29271\/jcpsp.2022.06.763.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"6","key":"3011_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/MCO.0000000000000099","volume":"17","author":"GA ten Hoor","year":"2014","unstructured":"ten Hoor GA, Plasqui G, Schols AM, Kok G. Combating adolescent obesity: an integrated physiological and psychological perspective. Curr Opin Clin Nutr Metab Care. 2014;17(6):521\u20134. https:\/\/doi.org\/10.1097\/MCO.0000000000000099.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"4","key":"3011_CR33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/apt.17598","volume":"58","author":"M Romero-G\u00f3mez","year":"2023","unstructured":"Romero-G\u00f3mez M, Armstrong MJ, Funuyet-Salas J, et al. Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: a randomised trial. Aliment Pharmacol Ther. 2023;58(4):395\u2013403. https:\/\/doi.org\/10.1111\/apt.17598.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"3011_CR34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. The Lancet Gastroenterology & Hepatology. 2023;8(6):511\u201322. https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"12","key":"3011_CR35","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2028395.","journal-title":"N Engl J Med"},{"issue":"9","key":"3011_CR36","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/apt.16608","volume":"54","author":"A Flint","year":"2021","unstructured":"Flint A, Andersen G, Hockings P, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021;54(9):1150\u201361. https:\/\/doi.org\/10.1111\/apt.16608.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-03011-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-025-03011-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-03011-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:04:04Z","timestamp":1768842244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13643-025-03011-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3011"],"URL":"https:\/\/doi.org\/10.1186\/s13643-025-03011-x","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}